Detailed Narrative
Biocon Integration and Margin Expansion
The turnaround of the Biocon segment remains a core driver for Eris, with Q2 EBITDA margins reaching 32%, a significant jump from the 19% seen at acquisition. Management expects further expansion as in-house manufacturing of insulin at the Bhopal facility stabilizes. The company has already produced ~2 million vials since going live in August, aiming for full vertical integration in drug substance and drug product.
International Business Inflection Point
The international business, centered on Swiss Parenterals, is nearing a major inflection point starting FY27. The EU-CDMO order book has expanded dramatically from ₹100 crores to ₹700-800 crores in just one quarter. Eris received its first purchase order from a European client for an injectable CDMO project, providing revenue visibility of ₹125-150 crores for the next financial year with margins consistent with the business average.
The $1 Billion GLP-1 Opportunity
Chairman Amit Bakshi highlighted the GLP-1 segment as a transformative opportunity, estimating the Indian market could reach $1 billion in its first year post-patent expiry. Eris is positioning itself as a dominant player, leveraging its insulin selling experience and 'hand-holding' capabilities. Management believes the market will be split 60/40 between Indian generic players and MNCs, with Eris aiming to be a significant participant.
Capex Front-loading and Deleveraging
Eris is front-loading its capex plans to capture lucrative opportunities in diabetes and injectables, with ₹380-400 crores of investment planned over the next three quarters. This includes the Bhopal Phase 2 expansion (₹150 crores) and Swiss Unit-3 (₹130 crores). Despite this heavy spend, the company remains committed to deleveraging, targeting a net debt-to-EBITDA ratio of 1.3x by December 2026, down from 2x currently.
Domestic Growth and Pipeline Challenges
While DBF grew 10% in Q2, management acknowledged missing their target of 50% outperformance over the market due to the cancellation of the gSaxenda launch and delayed price hikes. However, the price increases taken in late H1 are expected to provide a tailwind for H2. The company also expects to monetize the RHI cartridge opportunity starting December 2025, which will be additive to current growth visibility.